285 Recruiting Trials

Clinical Trials
for Cancer in Indiana

285 clinical trials for Cancer are currently recruiting participants at study sites in Indiana. Study-related care is provided at no cost.

285
Recruiting trials
190
Study sites
30
Cities
158
Industry-sponsored
97
Phase 2
120
Phase 3

Cancer clinical trials in Indiana: what to expect

Cancer is the single largest area of clinical research, and nearly every recruiting cancer trial is written for one cancer type at one stage. Most test a new drug or combination against the current standard treatment: targeted medicines matched to a mutation found in the tumor, immunotherapies that help the immune system recognize cancer cells, antibody-drug conjugates and cell therapies. Others study surgery and radiation techniques, ways to reduce side effects, and screening or prevention in people at higher risk.

In Indiana, recruiting cancer studies are concentrated in Indianapolis, Fort Wayne, Crown Point and Dyer, with sites in 26 other cities. 158 of the 285 are run by a drug or device company, which usually means a larger study with travel reimbursement; the rest are academic or hospital-led.

Who cancer trials usually look for

Every listing names the cancer type and stage it enrolls, and most also state how many earlier treatments you may have had: some are for people newly diagnosed, many are for cancer that has come back or spread after a first treatment stopped working. Targeted-therapy trials require a specific result on tumor testing, which the site can arrange if it has not been done. Trials generally ask that you are well enough for daily activity (a "performance status" the doctor scores), that blood counts and liver and kidney function are adequate, and that a few weeks have passed since your last treatment.

Having advanced or metastatic cancer does not rule you out. A large share of recruiting trials are designed specifically for it.

What taking part involves

Screening reviews your pathology and scans, often with new blood work and sometimes a fresh biopsy. Treatment then follows a cycle, typically every two or three weeks, with scans every six to twelve weeks to measure the response. Early-phase trials have more frequent visits at the start. The study drug and study-specific tests are provided at no cost; standard care that you would receive anyway is usually billed to insurance as normal. A placebo on its own is rare in cancer trials: when there is one, it is added to the standard treatment, and the consent form says so.

Questions worth asking the study team

Whether the trial is randomized and what the comparison treatment is; what happens if the cancer grows during the study; whether you can keep receiving the drug afterward if it is working; how the trial fits with the plan your own oncologist has suggested; and what travel or lodging support is offered. Your oncologist can also refer you directly.

Showing 20 of 285 recruiting Cancer trials in Indiana

Childhood Cancer Survivor Study
N/A Birmingham, Alabama +4 sites NCT01120353
This trial is looking for childhood cancer survivors who were diagnosed before age 21 and survived for at least five years. Participants will be followed to understand the long-term effects of their cancer treatments.
Recruiting
Integrated Cancer Repository for Cancer Research
N/A Greenwood Village, Colorado +4 sites NCT02012699
This trial is looking for adults who have a history of cancer, are at risk for developing cancer, or are healthy individuals. Participants will provide consent and may help advance cancer research by sharing data and samples.
Recruiting
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
PHASE3 Tucson, Arizona +4 sites NCT06136650
This trial is looking for men with metastatic castration-resistant prostate cancer who have been treated with one hormonal therapy before. Participants will receive either opevesostat with corticosteroids or other alternative treatments to see which is more effective.
Recruiting
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
PHASE3 Anchorage, Alaska +4 sites NCT06801834
This trial is looking for patients with extensive stage small cell lung cancer that has been treated before. Participants will receive the study drug sacituzumab govitecan to see how it works compared to standard treatment.
Recruiting
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
PHASE3 Birmingham, Alabama +4 sites NCT06901531
This trial is looking for adults with advanced stomach or gastroesophageal junction cancer. Participants will receive a combination of zolbetuximab, pembrolizumab, and chemotherapy, or a placebo with pembrolizumab and chemotherapy to see how well it works.
Recruiting
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
PHASE3 Jonesboro, Arkansas +4 sites NCT07391774
This trial is looking for women who are postmenopausal and have high stage breast cancer that is less likely to come back. Participants will compare hormone therapy and ribociclib to chemotherapy followed by hormone therapy and ribociclib.
Recruiting
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
PHASE3 Birmingham, Alabama +4 sites NCT04928846
This trial is looking for adults with a type of lung cancer who have already had treatment. Participants will receive either telisotuzumab vedotin or docetaxel through an IV every couple of weeks to see how well they work and how safe they are.
Recruiting
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
PHASE3 Birmingham, Alabama +4 sites NCT05827081
This trial is looking for adults with early breast cancer that is hormone receptor positive and HER2 negative. If you join, you will receive ribociclib along with standard hormone therapy to see how effective this combination is.
Recruiting
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
PHASE3 Birmingham, Alabama +4 sites NCT06058377
This trial is looking for women with hormone receptor positive, HER2 negative stage II-III breast cancer. Participants will receive standard chemotherapy along with an immunotherapy drug called durvalumab to see if it helps prevent cancer from coming back.
Recruiting
Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.
PHASE3 Cerritos, California +4 sites NCT07217704
This trial is looking for adults with gastric, esophageal, or gastroesophageal cancer who are evaluating their treatment options. Participants will receive a PET scan with a special substance to help detect cancer spread.
Recruiting
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
PHASE3 Anchorage, Alaska +4 sites NCT06764875
This trial is looking for individuals with advanced stomach cancer that tests positive for HER2. Participants will receive a combination of rilvegostomig, chemotherapy, and other treatments to see how well it works.
Recruiting
BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
PHASE3 Birmingham, Alabama +4 sites NCT07492641
This trial is looking for people with advanced breast cancer who have not been treated for it before. Participants will receive either BGB-43395 with letrozole or a different treatment option with letrozole.
Recruiting
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
PHASE3 Little Rock, Arkansas +4 sites NCT06312137
This trial is looking for adults with a type of lung cancer called non-small cell lung cancer who did not have a complete response after surgery. Participants will receive medications to see if adding sacituzumab to pembrolizumab helps them stay cancer-free longer.
Recruiting
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
PHASE2 Birmingham, Alabama +4 sites NCT06712316
This trial is looking for people with advanced non-small cell lung cancer who have not received any treatment yet. Participants will receive a new treatment combined with chemotherapy and will be monitored for their health outcomes.
Recruiting
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
PHASE3 Tucson, Arizona +4 sites NCT06712355
This trial is looking for patients with untreated extensive-stage small-cell lung cancer. Participants will receive either BNT327 combined with chemotherapy or a different combination of treatments to see which works better.
Recruiting
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
PHASE3 Phoenix, Arizona +4 sites NCT06952803
This trial is looking for men with high-risk prostate cancer who have a specific gene mutation. Participants will receive either the drug Saruparib or a placebo along with standard radiation and hormone therapy to see how well they can avoid cancer spread.
Recruiting

Where the Cancer studies are in Indiana

  • Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis25 trials
  • Reid Health, Richmond24 trials
  • Northwest Oncology LLC, Dyer22 trials
  • Saint Mary Medical Center, Hobart22 trials
  • The Community Hospital, Munster22 trials
  • Northwest Cancer Center - Valparaiso, Valparaiso21 trials

Counts are recruiting studies listing at least one site in Indiana, from ClinicalTrials.gov, refreshed every two days.

Cancer clinical trials in Indiana: common questions

How many Cancer clinical trials are recruiting in Indiana?
TrialFinder currently lists 285 recruiting Cancer clinical trials with study sites in Indiana. Results are updated regularly from ClinicalTrials.gov, the official U.S. registry of clinical studies.
Where are Cancer clinical trials located in Indiana?
Study sites for the Cancer trials listed on this page include Fort Wayne, Indianapolis. Each trial page lists every participating site with contact details, so you can find the location closest to you.
Do I need insurance to join a Cancer clinical trial in Indiana?
No. Study-related care is covered by the trial sponsor at no cost to participants, including the study treatment, required lab tests and study visits. Many Cancer trials in Indiana also compensate participants for time and travel. Health insurance is not required to search or enroll.
How do I qualify for a Cancer clinical trial in Indiana?
Each study sets its own criteria based on age, Cancer diagnosis details, prior treatments, current medications and general health. The fastest way to find out is to contact a research site directly — most will pre-screen you by phone in 10 to 15 minutes at no charge. You can also create a free TrialFinder profile to be matched automatically.
Will I get a placebo instead of cancer treatment?
Almost never. Cancer trials compare a new treatment with the current standard treatment, or add the study drug to standard treatment. When a placebo is used it is on top of standard care, and the consent form states this before you decide.
Can I join a cancer trial if my cancer has spread?
Yes. Many recruiting cancer trials are written for advanced or metastatic disease, including people whose earlier treatments have stopped working. The listing states the stage and prior treatments it accepts.
Do I have to stop my current cancer treatment to join a trial?
It depends on the trial. Some enroll people whose current treatment has stopped working, some add the study drug to the treatment you are on, and some are for people who have not started treatment yet. Ask the study team before changing anything.
Are Clinical Trials Safe? What Patients Should Know
How clinical trial safety works — phases, IRB oversight, informed consent, and your right to withdraw — plus the real risks and questions to ask.
How to Know If You Qualify for a Clinical Trial
Every trial has eligibility criteria based on diagnosis, age, and medical history. Here's how to tell if you qualify — and what to do if you're not sure.
Clinical Trials Without Insurance: What You Need to Know
Clinical trials cover the cost of study-related care, making them one of the few ways to access treatment without health insurance. Here's what's covered.
All guides →

Check Your Eligibility

Create a free profile and our AI will match you to Cancer trials near you in Indiana.

Get Matched — Free
No insurance required

Breast cancer trials test new chemotherapy regimens, immunotherapy combinations, targeted therapies, and early-detection methods across all stages of breast cancer.

All Cancer trials →